Pleneva (BGC 200134)
/ Boston Scientific
- LARVOL DELTA
Home
Next
Prev
1 to 2
Of
2
Go to page
1
July 20, 2011
BTG plc: Annual general meeting and interim management statement
(BTG)
- P2a Trial of Pleneva nearing completion; Database lock is expected in Q3 2011 with additional data to follow from a six month open label study extension; Positive data from first P3 trial on Lemtrada reported in Jul 2011; Top-line results from the second pivotal P3 trial of Lemtrada expected in Q4 2011
Pipeline update • Multiple Sclerosis
June 06, 2011
Jefferies Global Healthcare Conference
(BTG)
- Pleneva / BTG; Anticipated P2a database lock anticipated in Q3 '11; Anticipated P2 data in 2011
Anticipated P2 data • Anticipated P2a database lock • Multiple Sclerosis • None
1 to 2
Of
2
Go to page
1